Actin-binding protein, Cytoskeletal regulator, Other
01
Overview
Profilin 1 (PFN1) is a small, highly conserved actin-binding protein found in all eukaryotic cells. The protein contains domains for actin, poly-L-proline, and phosphoinositide binding, enabling it to control actin polymerization and numerous cellular processes such as motility, division, trafficking, and signal transduction. PFN1 interacts with ligands like actin monomers, vasodilator-stimulated phosphoprotein (VASP), and signaling phosphoinositides. Altered PFN1 expression or disease-associated mutations (notably in ALS) affect the cytoskeleton and contribute to pathogenesis in cancers, neurodegenerative disorders, and other diseases. PFN1 is a critical modulator of cell movement and differentiation, especially in cancer, where it acts as a suppressor of invasion and metastasis in specific contexts, and is being explored for its potential as a prognostic biomarker and drug target.
Other names
PFN1Profilin-IActin-binding protein profilin-1
02
Mechanism of action
Mechanisms discussed in literature are typically centered on modulation of actin cytoskeleton dynamics. Drugs or peptides that alter PFN1 expression or function might influence cancer cell motility, invasion, and possibly neurotoxicity in ALS models.
03
Biological functions
Actin polymerization and depolymerizationCell motilityCell proliferationCell cycle regulationMembrane traffickingTranscription regulationApoptosisCellular signaling through phosphoinositidesCell adhesion and epithelial-mesenchymal transition (EMT)
04
Disease associations
Cancer (e.g., breast cancer, hepatocarcinoma)Neurodegenerative disease (amyotrophic lateral sclerosis, ALS)Cardiovascular disease (e.g., hypertension)Other chronic diseases (context-specific associations)
05
Safety considerations
Profilin 1 is ubiquitously expressed and vital for normal cellular functions, so targeting it directly presents risks of broad impacts on essential processes such as cell division, motility, and signaling.Disruption of PFN1 could alter normal cytoskeletal integrity, potentially causing toxicity or unintended effects in non-target tissues.The redundancy of profilin isoforms and context-dependent functions complicate direct therapeutic targeting.
06
Interacting drugs
There are currently no clinically approved drugs that specifically target Profilin 1. It is mostly addressed via research reagents (peptides, small molecules, recombinant proteins) in cell biology and preclinical studies. Its role as a therapeutic target is under investigation in oncology and neurodegeneration.
07
Biomarkers
PFN1 expression levels in tumors may serve as a potential biomarker for cancer prognosis (e.g., breast cancer, hepatocarcinoma)Mutations in PFN1 can be biomarkers in familial ALS
Beyond the preview
Go deeper on Profilin 1 (PFN1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Profilin 1 (PFN1).